Drugs / FT839
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07800871 | Oct 2026 → Oct 2028 expected | anti-neutrophil cytoplasmic antibody-associated vasculitis, idiopathic inflammatory myopathy, rheumatoid arthritis, systemic lupus erythematosus +1 | Fate Therapeutics | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-08-13 | Fate Therapeutics | Regulatory Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates fatetherapeutics.com ↗ |
| 2026-07-09 | Fate Therapeutics | Regulatory Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate fatetherapeutics.com ↗
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies broadly to patients with cancer and autoimmune disease, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for FT839, the Company’s next-generation, off-the-shelf CAR T-cell product candidate uniquely engineered to co-target CD19 and CD38. |
| 2026-06-04 | Fate Therapeutics | Results Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting fatetherapeutics.com ↗
Sword and Shield™ engineering enabled FT839 to specifically suppress the emergence of alloreactive CD25+4-1BB+ T cells while sustaining CD19 and CD38 cytotoxicity in allogeneic settings. |
| 2026-05-11 | Fate Therapeutics | Results Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting fatetherapeutics.com ↗
Preclinical data for FT839 demonstrate comprehensive targeting of multicellular disease across autoimmune and hematological malignancies; data shows broad and selective depletion of pathogenic immune cell subtypes in rheumatoid arthritis and systemic lupus erythematosus disease without the use of conditioning chemotherapy |
All press releases naming this drug 5 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FT839 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07800871 ↗ |
| Modality | Cell therapy | “allogeneic T cells targeting CD19 and CD38” NCT07800871 ↗ |
| Route | Intravenous | “Single Intravenous (IV) infusion of FT839 administered on Day 1 and Day 4” NCT07800871 ↗ |
| Target | CD19 | “allogeneic T cells targeting CD19 and CD38” NCT07800871 ↗ |
| Target | CD38 | “allogeneic T cells targeting CD19 and CD38” NCT07800871 ↗ |